MCID: SKN015
MIFTS: 67

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 11 53 14 16
Skin Cancer 11 19 53 41 2 14 75
Melanoma and Non-Melanoma Skin Cancer 11
Malignant Neoplasm of Skin 11
Carcinoma of Skin 11
Ca - Skin Cancer 11
Cancer of Skin 11
Skin Cancers 14
Cancer, Skin 38

Classifications:



External Ids:

Disease Ontology 11 DOID:3451 DOID:4159
MeSH 43 D012878
NCIt 49 C2920 C4914
SNOMED-CT 68 94047004
UMLS 71 C0007114 C0699893

Summaries for Skin Carcinoma

MedlinePlus: 41 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who : Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary: Skin Carcinoma, also known as skin cancer, is related to xeroderma pigmentosum, complementation group f and rothmund-thomson syndrome, type 2. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Homology Directed Repair and Transcription-Coupled Nucleotide Excision Repair (TC-NER). The drugs Petrolatum and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include tissues of the skin, skin and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased TP53 mRNA expression

CDC: 2 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

GARD: 19 A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.

Disease Ontology 11 Skin carcinoma: A skin cancer that is located in tissues of the skin and develops from epithelial cells.

Skin cancer: An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

Wikipedia: 75 Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells... more...

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 961)
# Related Disease Score Top Affiliating Genes
1 xeroderma pigmentosum, complementation group f 32.6 XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
2 rothmund-thomson syndrome, type 2 32.5 H2AC18 ERCC6 ERCC3 ERCC2
3 xeroderma pigmentosum, complementation group c 32.4 XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
4 acral lentiginous melanoma 32.4 TYR MC1R CDK4
5 xeroderma pigmentosum, complementation group a 32.3 XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
6 penis carcinoma in situ 32.3 TP53 PTCH1
7 basal cell nevus syndrome 32.3 TP53 PTCH1 MC1R
8 xeroderma pigmentosum, complementation group g 32.3 XPA POLH H2AC18 ERCC6 ERCC3 ERCC2
9 cockayne syndrome a 32.3 XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
10 epidermodysplasia verruciformis 1 32.2 TP53 TMC8 TMC6
11 xeroderma pigmentosum, complementation group d 32.2 XPA ERCC3 ERCC2
12 basal cell carcinoma 32.1 XPA TYR TP53 PTCH1 MC1R ICOSLG
13 trichothiodystrophy 32.1 XPA TP53 POLH H2AC18 ERCC6 ERCC3
14 cockayne syndrome b 32.1 XPA H2AC18 ERCC6 ERCC3 ERCC2 DDB2
15 cowden syndrome 32.0 TP53 PTCH1 MIR21 ERCC6
16 prostate cancer 31.9 TYR TP53 PTGS2 MIR21 JUN H2AC18
17 albinism, oculocutaneous, type ia 31.5 TYR MC1R
18 lymphoma, hodgkin, classic 31.4 TP53 MIR21 ICOSLG H2AC18 CCR6
19 vitiligo-associated multiple autoimmune disease susceptibility 1 31.4 TYR MC1R ICOSLG CCR6
20 melanoma in congenital melanocytic nevus 31.2 TYR TP53 MIR21 MC1R H2AC18 CDK4
21 telangiectasis 31.1 TP53 H2AC18 ERCC6 CCR6
22 viral infectious disease 31.1 MIR21 ICOSLG H2AC18 CCR6
23 head and neck cancer 31.0 TP53 MIR21 ICOSLG H2AC18 ERCC6 CCR6
24 basosquamous carcinoma 31.0 TP53 PTCH1
25 lymphoma, non-hodgkin, familial 31.0 TP53 MIR21 ICOSLG H2AC18 CCR6 CASP3
26 primary cutaneous t-cell non-hodgkin lymphoma 31.0 MIR21 H2AC18 CCR6
27 skin benign neoplasm 31.0 XPA TYR TP53 PTCH1 JUN ERCC3
28 cockayne syndrome 30.9 XPA TP53 JUN ERCC6 ERCC3 ERCC2
29 systemic scleroderma 30.8 MIR21 ICOSLG H2AC18 CCR6
30 actinic keratosis 30.8 XPA TP53 TMC8 PTGS2 MC1R H2AC18
31 melanoma, cutaneous malignant 1 30.8 TYR TP53 MC1R ERCC2 CDK4
32 melanoma 30.8 TYR TP53 MIR21 MC1R JUN DDB2
33 nodular malignant melanoma 30.8 TYR TP53 MC1R CDK4
34 anogenital venereal wart 30.8 TP53 TMC8 H2AC18 CCR6
35 ataxia-telangiectasia 30.8 XPA TP53 JUN ERCC3 CASP3
36 exanthem 30.8 ICOSLG H2AC18 CCR6
37 adult t-cell leukemia/lymphoma 30.8 TP53 ICOSLG H2AC18 CCR6
38 t-cell acute lymphoblastic leukemia 30.7 JUN ICOSLG H2AC18 CDK4 CCR6 CASP3
39 squamous cell carcinoma, head and neck 30.7 TP53 PTGS2 MIR21 JUN ICOSLG H2AC18
40 kidney cancer 30.7 TP53 MIR21 ICOSLG H2AC18 CCR6
41 allergic disease 30.7 MIR21 ICOSLG H2AC18 CCR6
42 papilloma 30.7 TP53 PTGS2 CCR6 CASP3
43 myelodysplastic syndrome 30.7 TP53 ICOSLG H2AC18 CDK4 CCR6 CASP3
44 li-fraumeni syndrome 30.6 TP53 PTCH1 H2AC18 CDK4
45 contact dermatitis 30.6 MIR21 ICOSLG CCR6
46 crohn's disease 30.6 MIR21 ICOSLG H2AC18 CCR6
47 deficiency anemia 30.6 TP53 ICOSLG H2AC18 ERCC6 CCR6
48 skin melanoma 30.6 TYR TP53 MIR21 MC1R ICOSLG H2AC18
49 common wart 30.6 TP53 TMC8 TMC6
50 body mass index quantitative trait locus 11 30.6 TP53 PTGS2 MIR21 MC1R JUN ICOSLG

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 DDB2 ERCC6 JUN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 DDB2 ERCC6 JUN TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.8 DDB2 ERCC2 ERCC3 ERCC6 JUN POLH
4 Increased TP53 mRNA expression GR00389-S-5 8.32 JUN

MGI Mouse Phenotypes related to Skin Carcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
2 growth/size/body region MP:0005378 10.38 CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6
3 neoplasm MP:0002006 10.34 CDK4 DDB2 ERCC2 ERCC3 ERCC6 MC1R
4 nervous system MP:0003631 10.31 CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
5 immune system MP:0005387 10.24 CASP3 CCR6 CDK4 ERCC2 ERCC6 ICOSLG
6 pigmentation MP:0001186 10.22 CASP3 CDK4 ERCC2 MC1R POLH PTCH1
7 cellular MP:0005384 10.22 CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6
8 endocrine/exocrine gland MP:0005379 10.16 CASP3 CDK4 ERCC2 ERCC3 JUN PTCH1
9 muscle MP:0005369 10.13 CASP3 CDK4 ERCC3 ERCC6 PTCH1 PTGS2
10 craniofacial MP:0005382 10.13 CASP3 CDK4 ERCC3 JUN MC1R POLH
11 no phenotypic analysis MP:0003012 10.09 CASP3 JUN MC1R PTCH1 PTGS2 TP53
12 reproductive system MP:0005389 10.06 CASP3 CDK4 ERCC2 ERCC3 PTCH1 PTGS2
13 hearing/vestibular/ear MP:0005377 10.04 CASP3 ERCC6 MC1R POLH PTCH1 TP53
14 skeleton MP:0005390 10.03 CASP3 CDK4 ERCC2 ERCC3 ERCC6 JUN
15 vision/eye MP:0005391 9.85 CASP3 CDK4 ERCC2 ERCC6 JUN PTCH1
16 hematopoietic system MP:0005397 9.83 CASP3 CCR6 CDK4 ERCC2 ERCC3 ERCC6
17 integument MP:0010771 9.53 CASP3 CDK4 DDB2 ERCC2 ERCC3 ERCC6

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Petrolatum Approved, Investigational Phase 4 8009-03-8
2
Etanercept Approved, Investigational Phase 4 185243-69-0
3
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430
4
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
7
Azathioprine Approved Phase 4 446-86-6 2265
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
9
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13 Dermatologic Agents Phase 4
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Gastrointestinal Agents Phase 4
17 Erythromycin stearate Phase 4
18 Erythromycin Ethylsuccinate Phase 4
19 Erythromycin Estolate Phase 4
20 Polymyxins Phase 4
21 Lubricant Eye Drops Phase 4
22 Calcineurin Inhibitors Phase 4
23 Cyclosporins Phase 4
24 Anti-Bacterial Agents Phase 4
25 Anti-Infective Agents Phase 4
26 Antifungal Agents Phase 4
27 Antimetabolites Phase 4
28 Antibiotics, Antitubercular Phase 4
29 Neurotransmitter Agents Phase 4
30 Agglutinins Phase 4
31
abobotulinumtoxinA Phase 4
32 Botulinum Toxins, Type A Phase 4
33 Botulinum Toxins Phase 4
34 Hemagglutinins Phase 4
35 Cholinergic Agents Phase 4
36
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
37
Aminolevulinic acid Approved Phase 3 106-60-5 137
38
Eflornithine Approved, Withdrawn Phase 3 70052-12-9 3009
39
Acetaminophen Approved Phase 3 103-90-2 1983
40
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
41
Vinblastine Approved Phase 3 865-21-4 241903 13342
42
Dacarbazine Approved, Investigational Phase 3 4342-03-4 2942 5351166
43
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
44
Linrodostat Investigational Phase 3 1923833-60-6 121328278
45 Radiation-Protective Agents Phase 2, Phase 3
46 Sunscreening Agents Phase 2, Phase 3
47 Protective Agents Phase 2, Phase 3
48 Photosensitizing Agents Phase 3
49 Antiprotozoal Agents Phase 3
50 Antiparasitic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 385)
# Name Status NCT ID Phase Drugs
1 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
2 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
3 The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery Completed NCT03199911 Phase 4 Topical Antibiotic Product;Topical Non-Antibiotic Ointment
4 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
5 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
6 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
7 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
8 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
9 A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated Completed NCT03329846 Phase 3 BMS-986205;Placebo
10 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
11 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
12 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
13 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
14 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
15 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
16 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
17 Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2 Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
18 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
19 Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial Completed NCT04549675 Phase 3
20 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
21 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
22 Risk Information and Skin-Cancer Education and Undergraduate Prevention Trial Not yet recruiting NCT05634252 Phase 3
23 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
24 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
25 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
26 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
27 A Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and Neck Unknown status NCT04435938 Phase 2
28 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
29 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma Completed NCT00804908 Phase 2 temozolomide;ABT-888
30 Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours Completed NCT01861496 Phase 1, Phase 2 LiPlaCis
31 Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes Completed NCT00509288 Phase 2 Cyclophosphamide;Fludarabine
32 Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma Completed NCT00520299 Phase 1, Phase 2 ADI PEG 20
33 A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck Completed NCT01835626 Phase 2 Vismodegib
34 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin Completed NCT00665470 Phase 2 Aldesleukin
35 Study of Talabostat and Cisplatin in Advanced Melanoma Completed NCT00083252 Phase 2 talabostat (PT-100) tablets;cisplatin
36 Study of Talabostat in Advanced Melanoma Completed NCT00083239 Phase 2 talabostat (PT-100) tablets
37 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
38 Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
39 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas Completed NCT01108094 Phase 2 Itraconazole
40 Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms Completed NCT00021294 Phase 2 eflornithine;triamcinolone
41 A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
42 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
43 A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer Completed NCT00089180 Phase 2 liposomal T4N5 lotion
44 A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses Completed NCT00002975 Phase 2 aminolevulinic acid
45 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
46 Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines Completed NCT00923195 Phase 2 MART-1: 26-35(27L) Peptide;Montanide ISA 51 VG;gp100:154-162 Peptide;Aldesleukin;Fludarabine;Cyclophosphamide
47 A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome Completed NCT00023621 Phase 2 celecoxib
48 Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma Completed NCT00295958 Phase 2
49 Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Completed NCT00885534 Phase 2 Cisplatin, Vinblastine, Temozolomide
50 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib

Search NIH Clinical Center for Skin Carcinoma

Genetic Tests for Skin Carcinoma

Anatomical Context for Skin Carcinoma

Organs/tissues related to Skin Carcinoma:

FMA: Tissues Of The Skin, Skin
MalaCards : Skin, Lymph Node, Breast, Lung, Liver, Kidney, Heart

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 26358)
# Title Authors PMID Year
1
Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. 41
36251220 2022
2
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. 41
35964471 2022
3
Describing, predicting and explaining adherence to total skin self-examination (TSSE) in people with melanoma: a 12-month longitudinal study. 41
36041758 2022
4
Signaling pathways in melanosome biogenesis and pathology. 53 62
20381640 2010
5
Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. 53 62
20096264 2010
6
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. 53 62
20399617 2010
7
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. 53 62
19818066 2010
8
Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. 53 62
20129839 2010
9
Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. 53 62
20008555 2010
10
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. 53 62
20126537 2010
11
Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging. 53 62
20066389 2010
12
Mutagenesis: mutating a gene while reading it. 53 62
20129038 2010
13
MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. 53 62
19601983 2009
14
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. 53 62
19667145 2009
15
Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. 53 62
19445931 2009
16
Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. 53 62
19452503 2009
17
Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. 53 62
19384953 2009
18
Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. 53 62
19524636 2009
19
DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. 53 62
19564618 2009
20
Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. 53 62
19320745 2009
21
Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients. 53 62
19338054 2009
22
c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. 53 62
19204086 2009
23
p53 protein expression in skin with different levels of photoaging. 53 62
19292788 2009
24
Vitamin D and skin cancer: a meta-analysis. 53 62
19008093 2009
25
The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. 53 62
18637131 2009
26
Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. 53 62
19096907 2009
27
Differential activity of UV-DDB in mouse keratinocytes and fibroblasts: impact on DNA repair and UV-induced skin cancer. 53 62
18996499 2009
28
The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. 53 62
19577853 2009
29
Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients. 53 62
18817897 2008
30
Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene. 53 62
19017395 2008
31
Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. 53 62
18470933 2008
32
Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. 53 62
18787544 2008
33
A novel AKT3 mutation in melanoma tumours and cell lines. 53 62
18813315 2008
34
Prenatal manifestation in a family affected by nevoid basal cell carcinoma syndrome. 53 62
18539553 2008
35
Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. 53 62
18586118 2008
36
Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. 53 62
18647306 2008
37
Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. 53 62
18469853 2008
38
Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. 53 62
18510673 2008
39
Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. 53 62
18412244 2008
40
p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. 53 62
18219279 2008
41
FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis. 53 62
18558995 2008
42
Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. 53 62
18292087 2008
43
Melanocytes expressing MC1R polymorphisms associated with red hair color have altered MSH-ligand activated pigmentary responses in coculture with keratinocytes. 53 62
17960564 2008
44
Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. 53 62
18191509 2008
45
MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. 53 62
18067130 2008
46
Nucleotide diversity and population differentiation of the melanocortin 1 receptor gene, MC1R. 53 62
18402696 2008
47
Comparison of induced and cancer-associated mutational spectra using multivariate data analysis. 53 62
18296683 2008
48
Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. 53 62
18194346 2008
49
The melanocortin 1 receptor and the UV response of human melanocytes--a shift in paradigm. 53 62
18282187 2008
50
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). 53 62
17939062 2008

Variations for Skin Carcinoma

Cosmic variations for Skin Carcinoma:

8 (show top 50) (show all 2121)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144653327 TP53 skin,face,carcinoma,NS c.*131C>T p.? 17:7670685-7670685 18
2 COSM112254631 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 18
3 COSM143371865 TP53 skin,face,carcinoma,NS c.469C>T p.R157* 17:7674945-7674945 18
4 COSM93183824 TP53 skin,face,carcinoma,NS c.680C>T p.S227F 17:7674283-7674283 18
5 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 18
6 COSM121875437 TP53 skin,face,carcinoma,squamous cell carcinoma c.178C>T p.Q60* 17:7674957-7674957 18
7 COSM143388508 TP53 skin,face,carcinoma,squamous cell carcinoma c.629G>C p.R210T 17:7674217-7674217 18
8 COSM111758868 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 18
9 COSM142570304 TP53 skin,face,carcinoma,NS c.715C>T p.P239S 17:7673788-7673788 18
10 COSM142560384 TP53 skin,face,carcinoma,squamous cell carcinoma c.616G>T p.G206C 17:7674230-7674230 18
11 COSM142742951 TP53 skin,face,carcinoma,NS c.315G>A p.Q105= 17:7675180-7675180 18
12 COSM105639284 TP53 skin,face,carcinoma,NS c.712T>A p.C238S 17:7674251-7674251 18
13 COSM112253879 TP53 skin,face,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 18
14 COSM121878773 TP53 skin,face,carcinoma,NS c.241C>T p.R81* 17:7674894-7674894 18
15 COSM111776406 TP53 skin,face,carcinoma,NS c.993+1G>A p.? 17:7673534-7673534 18
16 COSM142837551 TP53 skin,face,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 18
17 COSM122742188 TP53 skin,face,carcinoma,NS c.58C>T p.P20S 17:7675158-7675158 18
18 COSM122735020 TP53 skin,face,carcinoma,NS c.190C>T p.R64* 17:7674945-7674945 18
19 COSM144028845 TP53 skin,face,carcinoma,NS c.679T>A p.C227S 17:7674251-7674251 18
20 COSM144021997 TP53 skin,face,carcinoma,squamous cell carcinoma c.421C>T p.P141S 17:7675158-7675158 18
21 COSM144015364 TP53 skin,face,carcinoma,NS c.604C>T p.R202* 17:7674894-7674894 18
22 COSM121877621 TP53 skin,face,carcinoma,NS c.190C>T p.R64* 17:7674945-7674945 18
23 COSM93201188 TP53 skin,face,carcinoma,NS c.993+1G>A p.? 17:7673534-7673534 18
24 COSM144658487 TP53 skin,face,carcinoma,squamous cell carcinoma c.143C>A p.P48Q 17:7676109-7676109 18
25 COSM142639459 TP53 skin,face,carcinoma,squamous cell carcinoma c.597T>A p.C199* 17:7674249-7674249 18
26 COSM105620390 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 18
27 COSM144014436 TP53 skin,face,carcinoma,NS c.553C>T p.R185* 17:7674945-7674945 18
28 COSM112253194 TP53 skin,face,carcinoma,NS c.833C>G p.P278R 17:7673787-7673787 18
29 COSM112263720 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 18
30 COSM122272676 TP53 skin,face,carcinoma,NS c.190C>T p.R64* 17:7674945-7674945 18
31 COSM93239210 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 18
32 COSM144651436 TP53 skin,face,carcinoma,NS c.625C>T p.R209W 17:7674221-7674221 18
33 COSM105620642 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 18
34 COSM144013959 TP53 skin,face,carcinoma,NS c.502C>T p.H168Y 17:7675077-7675077 18
35 COSM143949062 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 18
36 COSM121876459 TP53 skin,face,carcinoma,NS c.346C>T p.R116W 17:7674221-7674221 18
37 COSM111775215 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 18
38 COSM111765498 TP53 skin,face,carcinoma,NS c.854A>T p.E285V 17:7673766-7673766 18
39 COSM142838765 TP53 skin,face,carcinoma,NS c.*131C>T p.? 17:7670685-7670685 18
40 COSM93191278 TP53 skin,face,carcinoma,NS c.517G>A p.V173M 17:7675095-7675095 18
41 COSM144129318 TP53 skin,face,carcinoma,squamous cell carcinoma c.229T>C p.Y77H 17:7674257-7674257 18
42 COSM144088618 TP53 skin,face,carcinoma,squamous cell carcinoma c.160C>T p.R54* 17:7674894-7674894 18
43 COSM87910628 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 18
44 COSM87898709 TP53 skin,face,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 18
45 COSM144691571 TP53 skin,face,carcinoma,NS c.302C>T p.T101I 17:7675193-7675193 18
46 COSM144013187 TP53 skin,face,carcinoma,NS c.800C>G p.P267R 17:7673787-7673787 18
47 COSM143156943 TP53 skin,face,carcinoma,NS c.203C>T p.S68F 17:7674283-7674283 18
48 COSM144324830 TP53 skin,face,carcinoma,NS c.595T>A p.C199S 17:7674251-7674251 18
49 COSM144662686 TP53 skin,face,carcinoma,squamous cell carcinoma c.715C>T p.P239S 17:7673788-7673788 18
50 COSM144650676 TP53 skin,face,carcinoma,squamous cell carcinoma c.457C>T p.Q153* 17:7674957-7674957 18

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 XPA TP53 POLH H2AC18 ERCC6 ERCC3
2
Show member pathways
12.74 XPA ERCC6 ERCC3 ERCC2 DDB2
3
Show member pathways
12.72 TP53 JUN DDB2 CDK4 CASP3
4
Show member pathways
12.57 CASP3 CDK4 DDB2 JUN PTGS2 TP53
5
Show member pathways
12.44 XPA POLH ERCC6 ERCC3 ERCC2 DDB2
6
Show member pathways
12.36 TP53 PTGS2 JUN CASP3
7
Show member pathways
12.35 TP53 JUN DDB2 CDK4
8 12.33 TP53 PTGS2 JUN CDK4
9 12.17 XPA TP53 POLH ERCC3 ERCC2 DDB2
10
Show member pathways
12.09 XPA TP53 POLH ERCC6 ERCC3 ERCC2
11 12.04 TP53 JUN CDK4 CASP3
12
Show member pathways
12 TP53 DDB2 CDK4 CASP3
13 11.86 TP53 PTGS2 CDK4 CASP3
14
Show member pathways
11.74 ERCC6 ERCC3 ERCC2
15 11.64 TP53 PTGS2 DDB2 CDK4 CASP3
16 11.56 TP53 CDK4 CASP3
17
Show member pathways
11.56 PTGS2 JUN CDK4 CASP3
18 11.54 CDK4 TP53 TYR
19
Show member pathways
11.52 TP53 JUN CASP3
20 11.5 XPA TP53 JUN ERCC3 ERCC2
21 11.46 TP53 JUN CASP3
22 11.36 CASP3 JUN PTGS2 TP53
23 11.29 TP53 CDK4 CASP3
24 11.22 TP53 PTGS2 JUN
25 11.19 TP53 DDB2 CASP3
26 10.48 XPA POLH ERCC6 ERCC3 ERCC2

GO Terms for Skin Carcinoma

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.25 TP53 PTGS2 MIR21 JUN ERCC3 CASP3
2 DNA repair GO:0006281 10.24 XPA POLH ERCC6 ERCC3 ERCC2 DDB2
3 response to xenobiotic stimulus GO:0009410 10.22 TP53 PTGS2 PTCH1 JUN CDK4 CASP3
4 response to oxidative stress GO:0006979 10.11 ERCC2 ERCC3 ERCC6 PTGS2 TP53
5 cellular response to DNA damage stimulus GO:0006974 10.11 XPA TP53 POLH ERCC6 ERCC3 ERCC2
6 embryonic organ development GO:0048568 10.03 TP53 PTCH1 ERCC3
7 response to X-ray GO:0010165 10 CASP3 ERCC6 TP53
8 UV-damage excision repair GO:0070914 9.91 XPA MC1R DDB2
9 transcription-coupled nucleotide-excision repair GO:0006283 9.88 ERCC6 ERCC3 ERCC2
10 cellular response to UV-C GO:0071494 9.87 TP53 POLH
11 transcription elongation by RNA polymerase I GO:0006362 9.85 ERCC6 ERCC2
12 nucleotide-excision repair GO:0006289 9.81 XPA TP53 ERCC3 ERCC2 DDB2
13 pyrimidine dimer repair GO:0006290 9.8 DDB2 ERCC6 POLH
14 nucleotide-excision repair, DNA duplex unwinding GO:0000717 9.67 ERCC3 ERCC2
15 obsolete nucleotide-excision repair, DNA incision GO:0033683 9.56 XPA ERCC3 ERCC2
16 UV protection GO:0009650 9.56 XPA MC1R ERCC3 ERCC2
17 response to UV GO:0009411 9.4 TYR TP53 ERCC6 ERCC3 ERCC2 DDB2

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.56 TP53 ERCC6 ERCC3 ERCC2
2 DNA helicase activity GO:0003678 9.46 ERCC6 ERCC3 ERCC2
3 damaged DNA binding GO:0003684 9.32 XPA POLH ERCC3 ERCC2 DDB2

Sources for Skin Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....